Medical Pharmacology Practice Questions: Anti-Seizures; Anti-Epileptic Drugs

Ethosuxamide (Neurontin) is mainly used to treat this seizure type:
1. Generalized tonic-clonic seizures
2. Absence seizures
3. Infantile spasms
The mechanism of action of ethosuxamide in suppressing seizures is associated with this ion channel:
1. Sodium
2. Potassium
3. Chloride
4. Calcium
Choose which statement(s) concerning ethosuxamide pharmacokinetics is/are correct.
1. About 75% of ethosuxamide is excreted in the urine as the unchanged molecule
2. The major ethosuxamide metabolite is excreted as glucuronide (hydroxyethyl metabolite)
3. Both
4. Neither
The most frequently noted dose-related ethosuxamide side effect is gastrointestinal in nature.
1. True
2. False
Ethosuxamide is an effective against tonic-clonic seizures.
1. True
2. False
Seizure(s) which may be effectively managed by valproate:
1. Tonic-clonic seizures
2. Absence seizures
3. Myoclonic seizures
4. Partial seizures
5. A & B
6. B & C
7. A & C
8. A, B & C
9. A, B, C & D
10. A,B, C, D & E
Possible mechanism(s) associated with valproate antiseizure activity:
1. Induction of a prolonged recovery of voltage-activated sodium channels from the inactivated state
2. Slight reduction in T-type calcium currents
3. Effects on GABA metabolism
4. A & B
5. A, B & C
Tiagabine is characterized as an adjunct therapy for treating:
1. Partial seizures
2. Generalized tonic-clonic seizures
3. Both
4. Neither
Tiagabine's mechanism of antiseizure action is likely associated with this neurotransmitter system:
1. Cholinergic (nicotinic)
2. Cholinergic (muscarinic)
3. GABA
4. Glycine
5. Serotonergic
Choose (the) correct statement(s) concerning Tiagabine pharmacokinetics:
1. Tiagabine exhibits 90%-100% bioavailability
2. Hepatic impairment may necessitate a dosage reduction.
3. Tiagabine undergoes hepatic oxidation mediated by the CYP3A cytochrome P450 isoform.
4. A & C
5. A, B & C